1. Signaling Pathways
  2. Immunology/Inflammation
  3. Transmembrane Glycoprotein

Transmembrane Glycoprotein

Transmembrane Glycoprotein

Transmembrane glycoproteins are important components of cell membranes and are characterized by oligosaccharide chains covalently linked to polypeptide chains. Glycosylation sites are mainly located in their extracellular regions, achieved by N-linked glycosylation (linked to asparagine residues) or O-linked glycosylation (linked to serine or threonine residues). Sugar chains not only provide structural stability to proteins but also confer functional specificity. Many transmembrane glycoproteins are receptors, such as G protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs). Most (clusters of differentiation)CD molecules are also transmembrane glycoproteins expressed on the surface of antigen-presenting cells[1][2].

Transmembrane Glycoprotein Related Products (243):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-137605
    WSF1-IN-1
    Inhibitor 99.91%
    WSF1-IN-1 (compound 136), an orally active WSF1 inhibitor, can be used in the study for WSF1 (Wolfram syndrome) related tumors, with IC50 values of 0.33 μM and >27 μM in HepG2 parental and HepG2 WFS1 KO cell lines, respectively.
    WSF1-IN-1
  • HY-P990351
    Anti-CD34 Antibody
    Inhibitor 99.90%
    The Anti-CD34 Antibody is a human-derived antibody expressed in CHO, targeting CD34. The Anti-CD34 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD34 Antibody can be referenced from Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-CD34 Antibody
  • HY-P990496
    Anti-PVRIG Antibody (COM701)
    Inhibitor 99.14%
    Anti-PVRIG Antibody (COM701) is a CHO-expressed human antibody that targets PVRIG. The predicted molecular weight (MW) of Anti-PVRIG Antibody (COM701) is 145.48 kDa. The isotype control for Anti-PVRIG Antibody (COM701) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
    Anti-PVRIG Antibody (COM701)
  • HY-P991068
    hT84.66-M5A
    Inhibitor 99.03%
    hT84.66-M5A is a humanized IgG1 antibody that targets carcinoembryonic antigen (CEA). The isotype control for hT84.66-M5A can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    hT84.66-M5A
  • HY-P990061
    Polzastobart
    Inhibitor
    Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antagonist antibody that selectively binds LILRB2 and prevents it from binding its ligands, classical and non-classical MHC I molecules. Polzastobart enhances pro-inflammatory cytokine production in macrophages by blocking the ability of LILRB2 to bind HLA-A/B and/or HLA-G, a marker of immunotolerance on cancer cells. Polzastobart is a macrophage immune checkpoint inhibitor.
    Polzastobart
  • HY-P990328
    Anti-AGER/RAGE Antibody (XT-M4)
    Inhibitor ≥99.0%
    Anti-AGER/RAGE Antibody (XT-M4) is a humanized antibody expressed in CHO cells, targeting AGER/RAGE. Anti-AGER/RAGE Antibody (XT-M4) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-AGER/RAGE Antibody (XT-M4) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-AGER/RAGE Antibody (XT-M4)
  • HY-P990607
    Indatuximab
    Inhibitor 98.04%
    Indatuximab is a CHO-expressed, VHH-Fc (huIgG1) type chimeric antibody that targets Syndecan-1/CD138. The predicted molecular weight (MW) of Indatuximab is 146.1 kDa. The isotype control for Indatuximab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
    Indatuximab
  • HY-110104
    8MDP
    Inhibitor
    8MDP is a potent equilibrative nucleoside transporter 1 (ENT1) inhibitor with an IC50 of 0.43 nM. 8MDP inhibits hENT1 and hENT2 uptake of [H3] uridine by K562 cells and K15NTD cells.
    8MDP
  • HY-P990259
    Anti-Mouse CD96 Antibody (3.3)
    Inhibitor
    Anti-Mouse CD96 Antibody (3.3) is a rat-derived anti-mouse CD96 IgG1 λ type antibody inhibitor. Anti-Mouse CD96 Antibody (3.3) blocks binding of CD155 to CD96. Anti-Mouse CD96 Antibody (3.3) can enhance the antitumor efficacy of multiple immune-checkpoint inhibitors. Anti-Mouse CD96 Antibody (3.3) shows potent anti-tumor and anti-metastatic activity in various tumor models. Anti-Mouse CD96 Antibody (3.3) can be used for the researches of cancer and inflammation, such as mammary carcinoma.
    Anti-Mouse CD96 Antibody (3.3)
  • HY-P990827
    Anti-TROP-2 Antibody (Pr1E11)
    Anti-TROP-2 Antibody (Pr1E11) is a kind of mouse IgG1 κ chimeric antibody inhibitor, targeting to human TROP-2. Anti-TROP-2 Antibody (Pr1E11) reacts with human TROP-2, also known as TACSTD2 (Tumor-associated calcium signal transducer 2). Anti-TROP-2 Antibody (Pr1E11) can be used for the research of cancer, such as BxPC3 and Colo205 tumor.
    Anti-TROP-2 Antibody (Pr1E11)
  • HY-W081348
    1-(4-Methoxyphenyl)-3-methyl-1H-pyrazol-5(4H)-one
    99.54%
    1-(4-Methoxyphenyl)-3-methyl-1H-pyrazol-5(4H)-one (Compound 2) has antiprion activity in ScN2a and F3 cells with IC50 values of 13 nM and 25 nM, respectively.
    1-(4-Methoxyphenyl)-3-methyl-1H-pyrazol-5(4H)-one
  • HY-P2511
    Insulin β Chain Peptide (15-23)
    98.03%
    Insulin β Chain Peptide (15-23) is one of the earliest antigenic epitopes to which CD8 T-cells respond.
    Insulin β Chain Peptide (15-23)
  • HY-113481
    Prostaglandin E3
    Inhibitor ≥99.0%
    Prostaglandin E3 is an eicosanoid derived from eicosapentaenoic acid. Prostaglandin E3 inhibits polarization towards M1 but promotes polarization of M2a macrophages. Prostaglandin E3 shows anti-inflammatory and anti-tumor activity.
    Prostaglandin E3
  • HY-P990264
    Anti-Mouse CD70 Antibody (FR70)
    Inhibitor
    Anti-Mouse CD70 Antibody (FR70) is a rat-derived ant-mouse CD70 IgG2b κ type antibody inhibitor. Anti-Mouse CD70 Antibody (FR70) decreases CD4+, CD8+ T cells and eosinophils. Anti-Mouse CD70 Antibody (FR70) shows potent anti-inflammatory and anti-immune effects on allergic lung inflammation and cardiac transplant mice models.
    Anti-Mouse CD70 Antibody (FR70)
  • HY-170589
    GPR17 antagonist 1
    Antagonist 98.95%
    GPR17 antagonist 1 (compound 978) is a GPR17 antagonist. GPR17 antagonist 1 can be used in the study of diabetes and obesity.
    GPR17 antagonist 1
  • HY-P990092
    Rolistobart
    Inhibitor
    Rolistobart is a humanized immunoglobulin G4-kappa, anti-LILRB4/CD85k monoclonal antibody. Rolistobart is an immunostimulant and antineoplastic.
    Rolistobart
  • HY-128128
    ASN04421891
    Modulator 99.00%
    ASN04421891 is a potent GPR17 receptor modulator, with an EC50 of 3.67 nM in [35S]GTPγS binding assay. ASN04421891 can be used for neurodegenerative diseases research.
    ASN04421891
  • HY-165245
    SBI-183
    Inhibitor 99.8%
    SBI-183 is an orally active inhibitor of QSOX1 (Kd: 20 μM). SBI-183 suppresses the proliferative and invasive phenotype of renal cancer cell lines, including triple negative breast cancer cell line, lung adenocarcinoma cell line and pancreatic ductal adenocarcinoma. SBI-183 inhibits tumor growth in two human xenograft mouse models of renal cell carcinoma in vivo .
    SBI-183
  • HY-N8102
    Echinocystic acid 28-O-β-D-glucoside
    Inhibitor 99.11%
    Echinocystic acid 28-O-β-D-glucoside is a metabolite of Echinocystic acid by microbial oxidation and glucosidation. Echinocystic acid 28-O-β-D-glucoside is a tissue factor pathway inhibitor, with an IC50 of 10.61 nM.
    Echinocystic acid 28-O-β-D-glucoside
  • HY-P99674
    Ivicentamab
    Inhibitor 99.82%
    Ivicentamab (GEN-3009) is an IgG1κ-type bispecific antibody targeting different epitopes of CD37. Ivicentamab can be used for cancer research.
    Ivicentamab